{"id":13007,"date":"2010-03-09T10:30:00","date_gmt":"2010-03-09T09:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/farmaceutica-sfida-tricolore-ai-big\/"},"modified":"2010-03-09T10:30:00","modified_gmt":"2010-03-09T09:30:00","slug":"farmaceutica-sfida-tricolore-ai-big","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaceutica-sfida-tricolore-ai-big\/","title":{"rendered":"Pharmaceuticals: Italian challenge to the big names"},"content":{"rendered":"<p>The top three Italian pharmaceutical companies together invoice 4 billion euros a year: what the American Pfizer accounts for in a month. In this great gap, the Italian pharmaceutical sector aims to grow thanks to development in foreign markets, the study of rare diseases and betting on research at home. A solution well understood by Menarini (2.8 billion euros in turnover), Recordati (747 million euros) and Sigma-Tau (615 million euros), companies with share capital and strictly family control. A path also followed by Pierrel, who recently landed in the USA, Chiesi with the Research Center, Bracco, specialized in contrast media and Domp\u00e9, which has invested in studies on multiple sclerosis. CorrierEconomia Pag.1 \u2013 08\/03\/2010<\/p>","protected":false},"excerpt":{"rendered":"<p>Le prime tre aziende farmaceutiche italiane fatturano insieme 4 mld di euro all&#8217;anno: quello che l&#8217;americana Pfizer contabilizza in un mese. In questo grande divario, il settore farmaceutico italiano punta a crescere grazie allo sviluppo nei mercati esteri, lo studio di malattie rare e scommettendo sulla ricerca in casa. Un soluzione ben compresa da Menarini &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13007","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13007"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13007\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}